Technical Analysis for VCNX - Vaccinex, Inc.

Grade Last Price % Change Price Change
D 3.77 1.62% 0.06
VCNX closed up 13.8 percent on Wednesday, November 20, 2024, on 26 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Up Up

Date Alert Name Type % Chg
Crossed Above 20 DMA Bullish 1.62%
Crossed Above 50 DMA Bullish 1.62%
Wide Bands Range Expansion 1.62%
20 DMA Resistance Bearish 15.64%
Wide Bands Range Expansion 15.64%
Gapped Up Strength 15.64%
20 DMA Resistance Bearish 21.22%
Inside Day Range Contraction 21.22%
Wide Bands Range Expansion 21.22%
Bearish Engulfing Bearish 19.30%

   Recent Intraday Alerts

Alert Time
Rose Above Previous Day's High 40 minutes ago
Up 5% 40 minutes ago
Up 3% 40 minutes ago
Down 1% 40 minutes ago
Up 2% 40 minutes ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Vaccinex, Inc. Description

Vaccinex Inc. is a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics. The Company is focused on providing treatments for serious diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. It provides SEMA4D antibody platform, which is focused on developing its lead product candidate VX15/2503 (VX15) for the treatment of non-small cell lung cancer, NSCLC, osteosarcoma, melanoma and Huntington’s disease. It also provides ActiveMAb antibody discovery platform, a human antibody discovery platform used for expressing large and diverse libraries of high affinity, full-length human monoclonal antibodies on the surface of vaccinia, a mammalian virus. Its product candidate VX5 is in preclinical development for the treatment of multiple sclerosis and potentially for other autoimmune disorders.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Biology Immunology Immune System Antibodies Clinical Development Monoclonal Antibodies Antibody Non Small Cell Lung Cancer Melanoma Neurodegenerative Diseases Small Cell Lung Cancer Multiple Sclerosis Sarcoma Autoimmune Disorders Degenerative Disease Immune Disorders NSCLC Treatment Of Non Small Cell Lung Cancer Human Monoclonal Antibodies Osteosarcoma Treatment Of Multiple Sclerosis Seth Lederman Vaccinia

Is VCNX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 13.02
52 Week Low 1.39
Average Volume 115,578
200-Day Moving Average 5.81
50-Day Moving Average 3.37
20-Day Moving Average 3.36
10-Day Moving Average 3.33
Average True Range 0.47
RSI (14) 57.08
ADX 20.37
+DI 27.46
-DI 16.29
Chandelier Exit (Long, 3 ATRs) 3.40
Chandelier Exit (Short, 3 ATRs) 4.05
Upper Bollinger Bands 3.94
Lower Bollinger Band 2.77
Percent B (%b) 0.8
BandWidth 34.87
MACD Line 0.04
MACD Signal Line -0.01
MACD Histogram 0.0448
Fundamentals Value
Market Cap 46.35 Million
Num Shares 12.5 Million
EPS -5.99
Price-to-Earnings (P/E) Ratio -0.62
Price-to-Sales 10.83
Price-to-Book 3.05
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.37
Resistance 3 (R3) 4.30 4.01 4.26
Resistance 2 (R2) 4.01 3.84 4.05 4.22
Resistance 1 (R1) 3.86 3.74 3.94 3.93 4.19
Pivot Point 3.57 3.57 3.61 3.61 3.57
Support 1 (S1) 3.42 3.40 3.50 3.49 3.23
Support 2 (S2) 3.13 3.30 3.17 3.20
Support 3 (S3) 2.98 3.13 3.16
Support 4 (S4) 3.05